This study systematically evaluated the therapeutic effects of podophyllotoxin in a DSS-induced mouse model of ulcerative colitis. A total of 374 podophyllotoxin-related targets were identified through database screening, and by intersecting them with 1,741 UC-related targets, 120 potential therapeutic targets were obtained. Subsequent GO and KEGG enrichment analyses revealed that these targets are primarily involved in biological processes such as the positive regulation of protein kinase B signaling, cellular response to lipopolysaccharide, and inflammatory responses, with significant enrichment in key pathways like the PI3K-Akt signaling pathway. Molecular docking results indicated that podophyllotoxin has strong binding activity with several targets related to inflammation and signal transduction. Animal experiments further validated the significant therapeutic effects of podophyllotoxin in the DSS-induced ulcerative colitis mouse model. Particularly at high doses, podophyllotoxin effectively alleviated ulcerative colitis symptoms, reduced pathological damage to colonic tissues, and enhanced intestinal barrier function. Additionally, podophyllotoxin significantly lowered the levels of inflammatory cytokines (TNF-?, IL-1?, IL-6) in the serum and colonic tissues of ulcerative colitis model mice and improved oxidative stress status. More importantly, podophyllotoxin effectively restored the impaired intestinal mucosal barrier function by enhancing the expression of tight junction proteins such as ZO-1 and occludin. Finally, the study revealed that podophyllotoxin may alleviate ulcerative colitis symptoms and promote colonic tissue repair by activating the PI3K/AKT signaling pathway. These findings provide strong experimental evidence for the potential use of podophyllotoxin as a therapeutic agent for ulcerative colitis and offer valuable insights for the future development of ulcerative colitis treatment strategies targeting the PI3K/AKT pathway. Key words: Podophyllotoxin, Ulcerative Colitis, Inflammation, PI3K/AKT.

Department of Emergency The Affiliated Hospital of Southwest Medical University Luzhou Sichuan China

Zobrazit více v PubMed

Shah SC, Itzkowitz SH. Colorectal cancer in inflammatory bowel disease: mechanisms and management. Gastroenterology. 2022;162(3):715–30.e3. doi: 10.1053/j.gastro.2021.10.035. PubMed DOI PMC

Segal JP, LeBlanc J-F, Hart AL. Ulcerative colitis: an update. Clinical Medicine. 2021;21(2):135–9. doi: 10.7861/clinmed.2021-0080. PubMed DOI PMC

Nóbrega VG, SILVA INdN, Brito BS, Silva J, SILVA MCMd, Santana GO. The onset of clinical manifestations in inflammatory bowel disease patients. Arquivos de gastroenterologia. 2018;55(03):290–5. doi: 10.1590/s0004-2803.201800000-73. PubMed DOI

Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. Journal of medicine and life. 2019;12(2):113. doi: 10.25122/jml-2018-0075. PubMed DOI PMC

Gros B, Kaplan GG. Ulcerative colitis in adults: A review. Jama. 2023;330(10):951–65. doi: 10.1001/jama.2023.15389. PubMed DOI

Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Disease-a-month. 2019;65(12):100851. doi: 10.1016/j.disamonth.2019.02.004. PubMed DOI

Núñez FP, Quera R, Bay C, Castro F, Mezzano G. Drug-induced liver injury used in the treatment of inflammatory bowel disease. Journal of Crohn’s and Colitis. 2022;16(7):1168–76. doi: 10.1093/ecco-jcc/jjac013. PubMed DOI

Magro F, Cordeiro G, Dias AM, Estevinho MM. Inflammatory bowel disease-non-biological treatment. Pharmacological Research. 2020;160:105075. doi: 10.1016/j.phrs.2020.105075. PubMed DOI

Exarchos G, Gklavas A, Metaxa L, Papaconstantinou I. Quality of life of ulcerative colitis patients treated surgically with proctocolectomy and J-pouch formation: a comparative study before surgery and after closure of the defunctioning ileostomy. Annals of Gastroenterology. 2018;31(3):350. doi: 10.20524/aog.2018.0247. PubMed DOI PMC

Lee KE, Cantrell S, Shen B, Faye AS. Post-operative prevention and monitoring of Crohn’s disease recurrence. Gastroenterology Report. 2022;10:goac070. doi: 10.1093/gastro/goac070. PubMed DOI PMC

Motyka S, Jafernik K, Ekiert H, Sharifi-Rad J, Calina D, Al-Omari B, Szopa A, Cho WC. Podophyllotoxin and its derivatives: Potential anticancer agents of natural origin in cancer chemotherapy. Biomedicine & Pharmacotherapy. 2023;158:114145. doi: 10.1016/j.biopha.2022.114145. PubMed DOI

Fan H-y, Zhu Z-l, Xian H-c, Wang H-f, Chen B-j, Tang Y-J, Tang Y-l, Liang X-h. Insight into the molecular mechanism of podophyllotoxin derivatives as anticancer drugs. Frontiers in Cell and Developmental Biology. 2021;9:709075. doi: 10.3389/fcell.2021.709075. PubMed DOI PMC

Zhao W, Cong Y, Li H-M, Li S, Shen Y, Qi Q, Zhang Y, Li Y-Z, Tang Y-J. Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy. Natural Product Reports. 2021;38(3):470–88. doi: 10.1039/D0NP00041H. PubMed DOI

Hao M, Xu H. Chemistry and biology of podophyllotoxins: an update. Chemistry-A European Journal. 2024;30(4):e202302595. doi: 10.1002/chem.202302595. PubMed DOI

Lee S-O, Joo SH, Kwak A-W, Lee M-H, Seo J-H, Cho S-S, Yoon G, Chae J-I, Shim J-H. Podophyllotoxin induces ROS-mediated apoptosis and cell cycle arrest in human colorectal cancer cells via p38 MAPK signaling. Biomolecules & Therapeutics. 2021;29(6):658. doi: 10.4062/biomolther.2021.143. PubMed DOI PMC

Xu Y, He Z, Chen L, Wang H. Podophyllotoxin derivatives targeting tubulin: An update (2017–2022) Drug Discovery Today. 2023;28(8):103640. doi: 10.1016/j.drudis.2023.103640. PubMed DOI

Verma S, Kalita B, Bajaj S, Prakash H, Singh AK, Gupta ML. A combination of podophyllotoxin and rutin alleviates radiation-induced pneumonitis and fibrosis through modulation of lung inflammation in mice. Frontiers in immunology. 2017;8:658. doi: 10.3389/fimmu.2017.00658. PubMed DOI PMC

Shi R-j, Fan H-y, Yu X-h, Tang Y-l, Jiang J, Liang X-h. Advances of podophyllotoxin and its derivatives: Patterns and mechanisms. Biochemical Pharmacology. 2022;200:115039. doi: 10.1016/j.bcp.2022.115039. PubMed DOI

Suh S-J, Kim J-R, Jin U-H, Choi H-S, Chang Y-C, Lee Y-C, Kim S-H, Lee I-S, Moon TC, Chang H-W. Deoxypodophyllotoxin, flavolignan, from Anthriscus sylvestris Hoffm. inhibits migration and MMP-9 via MAPK pathways in TNF-α-induced HASMC. Vascular pharmacology. 2009;51(1):13–20. doi: 10.1016/j.vph.2008.10.004. PubMed DOI

Li Q, Zheng S, Niu K, Qiao Y, Liu Y, Zhang Y, Li B, Zheng C, Yu B. Paeoniflorin improves ulcerative colitis via regulation of PI3K-AKT based on network pharmacology analysis. Experimental and Therapeutic Medicine. 2024;27(4):1–12. https://doi.org/10.3892/etm.2024.12414 https://doi.org/10.3892/etm.2025.12827 https://doi.org/10.3892/etm.2025.12831 . PubMed DOI PMC

Zheng J-D, He Y, Yu H-Y, Liu Y-L, Ge Y-X, Li X-T, Li X, Wang Y, Guo M-R, Qu Y-L. Unconjugated bilirubin alleviates experimental ulcerative colitis by regulating intestinal barrier function and immune inflammation. World Journal of Gastroenterology. 2019;25(15):1865. doi: 10.3748/wjg.v25.i15.1865. PubMed DOI PMC

Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Experimental & molecular medicine. 2018;50(8):1–9. doi: 10.1038/s12276-018-0126-x. PubMed DOI PMC

Kumar MA, Khan TA, Al Marzooqi SK, Abdulla A, Masoodi T, Akil ASA-S, Bhat AA, Macha MA. Tight Junctions in Inflammation and Cancer. Springer; 2023. Molecular Architecture and Function of Tight Junctions; pp. 145–69. DOI

Moonwiriyakit A, Pathomthongtaweechai N, Steinhagen PR, Chantawichitwong P, Satianrapapong W, Pongkorpsakol P. Tight junctions: from molecules to gastrointestinal diseases. Tissue Barriers. 2023;11(2):2077620. doi: 10.1080/21688370.2022.2077620. PubMed DOI PMC

Slifer ZM, Blikslager AT. The integral role of tight junction proteins in the repair of injured intestinal epithelium. International journal of molecular sciences. 2020;21(3):972. doi: 10.3390/ijms21030972. PubMed DOI PMC

Reiche J, Huber O. Post-translational modifications of tight junction transmembrane proteins and their direct effect on barrier function. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2020;1862(9):183330. doi: 10.1016/j.bbamem.2020.183330. PubMed DOI

Dunleavy KA, Raffals LE, Camilleri M. Intestinal barrier dysfunction in inflammatory bowel disease: underpinning pathogenesis and therapeutics. Digestive diseases and sciences. 2023;68(12):4306–20. doi: 10.1007/s10620-023-08122-w. PubMed DOI PMC

Kuo W-T, Zuo L, Odenwald MA, Madha S, Singh G, Gurniak CB, Abraham C, Turner JR. The tight junction protein ZO-1 is dispensable for barrier function but critical for effective mucosal repair. Gastroenterology. 2021;161(6):1924–39. doi: 10.1053/j.gastro.2021.08.047. PubMed DOI PMC

Yu S, Sun Y, Shao X, Zhou Y, Yu Y, Kuai X, Zhou C. Leaky gut in IBD: Intestinal barrier-gut microbiota interaction. Journal of microbiology and biotechnology. 2022;32(7):825. doi: 10.4014/jmb.2203.03022. PubMed DOI PMC

Tan Y, Peng L, Wen L, Yang L, Zhu Y, Lai Y, Liu X, Liu F. Correlations of inflammatory cytokines in the intestinal mucosa, serum inflammation, oxidative stresses and immune changes with vitamin deficiency in ulcerative colitis patients. Cellular and Molecular Biology. 2022;68(7):101–6. doi: 10.14715/cmb/2022.68.7.17. PubMed DOI

Wang Y, Ren R, Sun G, Peng L, Tian Y, Yang Y. Pilot study of cytokine changes evaluation after fecal microbiota transplantation in patients with ulcerative colitis. International Immunopharmacology. 2020;85:106661. doi: 10.1016/j.intimp.2020.106661. PubMed DOI

Tatiya-Aphiradee N, Chatuphonprasert W, Jarukamjorn K. Immune response and inflammatory pathway of ulcerative colitis. Journal of basic and clinical physiology and pharmacology. 2018;30(1):1–10. doi: 10.1515/jbcpp-2018-0036. PubMed DOI

Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmunity reviews. 2022;21(3):103017. doi: 10.1016/j.autrev.2021.103017. PubMed DOI

Farré R, Fiorani M, Abdu Rahiman S, Matteoli G. Intestinal permeability, inflammation and the role of nutrients. Nutrients. 2020;12(4):1185. doi: 10.3390/nu12041185. PubMed DOI PMC

Barbara G, Barbaro MR, Fuschi D, Palombo M, Falangone F, Cremon C, Marasco G, Stanghellini V. Inflammatory and microbiota-related regulation of the intestinal epithelial barrier. Frontiers in nutrition. 2021;8:718356. https://doi.org/10.3389/fnut.2021.718356 https://doi.org/10.3389/fnut.2021.790387 . PubMed DOI PMC

Wan Y, Yang L, Jiang S, Qian D, Duan J. Excessive apoptosis in ulcerative colitis: crosstalk between apoptosis, ROS, ER stress, and intestinal homeostasis. Inflammatory bowel diseases. 2022;28(4):639–48. doi: 10.1093/ibd/izab277. PubMed DOI

Alzoghaibi MA, Al Mofleh IA, Al-Jebreen AM. Lipid peroxides in patients with inflammatory bowel disease. Saudi Journal of Gastroenterology. 2007;13(4):187–90. doi: 10.4103/1319-3767.36750. PubMed DOI

Ghulam Mohyuddin S, Khan I, Zada A, Qamar A, Arbab AAI, Ma X-b, Yu Z-c, Liu X-X, Yong Y-H, Ju XH. Influence of heat stress on intestinal epithelial barrier function, tight junction protein, and immune and reproductive physiology. BioMed Research International. 2022;2022(1):8547379. doi: 10.1155/2022/8547379. PubMed DOI PMC

Alzoghaibi MA, Al-Mofleh IA, Al-Jebreen AM. Antioxidant activities for superoxide dismutase in patients with Crohn’s disease. Journal of Basic and Clinical Physiology and Pharmacology. 2014;25(1):59–62. doi: 10.1515/jbcpp-2013-0042. PubMed DOI

Vaidya FU, Chhipa AS, Sagar N, Pathak C. Oxidative stress and inflammation can fuel cancer. Role of oxidative stress in pathophysiology of diseases. 2020:229–58. doi: 10.1007/978-981-15-1568-2_14. DOI

Zhu L, Shen H, Gu P-Q, Liu Y-J, Zhang L, Cheng J-F. Baicalin alleviates TNBS-induced colitis by inhibiting PI3K/AKT pathway activation. Experimental and therapeutic medicine. 2020;20(1):581–90. doi: 10.3892/etm.2020.8718. PubMed DOI PMC

Li C, Wang L, Zhao J, Wei Y, Zhai S, Tan M, Guan K, Huang Z, Chen C. Lonicera rupicola Hook. f. et Thoms flavonoids ameliorated dysregulated inflammatory responses, intestinal barrier, and gut microbiome in ulcerative colitis via PI3K/AKT pathway. Phytomedicine. 2022;104:154284. doi: 10.1016/j.phymed.2022.154284. PubMed DOI

Acosta-Martinez M, Cabail MZ. The PI3K/Akt pathway in meta-inflammation. International journal of molecular sciences. 2022;23(23):15330. doi: 10.3390/ijms232315330. PubMed DOI PMC